The Division of Pediatric Nephrology is dedicated to providing research, training, and a network of care for children and youth with kidney diseases.
The Pediatric Nephrology Fellowship Training Program was established in 1965. Graduates of our program provide high quality teaching and patient care, and demonstrate a continued dedication to improved understanding of disease through research based on the philosophy acquired during their training. A remarkable number of our graduates have successfully competed for NIH funding and other independent research support.
We offer one of top pediatric nephrology programs in the nation, and have performed the largest number of kidney transplants in the world. We have a very active dialysis and transplant program for children with end-stage kidney failure. We also boast the highest reported infant kidney transplant success rate in the world. The pediatric nephrologists work closely with a number of other specialties including pediatric urology, transplant surgery, pediatric psychology, nutrition, and social work to provide a multidisciplinary approach to the care of children with kidney disease.
We believe that advances in understanding and treating kidney disease in children requires highly motivated clinicians and scientists with specifc training in Pediatric Nephrology. Our physicians are uniquely trained to provide the best medical care and to share their passion for research and discovery.
The University of Minnesota's Department of Pediatrics has created the Alport Syndrome Treatments and Outcomes Registry (ASTOR). ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport syndrome. ASTOR also aims to provide patients, families and physicians with the most up-to-date information about Alport syndrome. This registry is the first of its kind in North America.
You can help doctors learn more about Alport syndrome and test possible treatments for the disease by enrolling in ASTOR. Since Alport syndrome is a rare disease it is essential for ASTOR to enroll as many patients as possible. Together, you and others facing the challenges of Alport syndrome can provide valuable information that will help doctors better understand the disease and in turn, help patients with Alport syndrome now and in the future.